Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Michael Leithead maintains an Equal-Weight rating on Chemours (NYSE:CC) but lowers the price target from $30 to $22.
August 06, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Michael Leithead maintains an Equal-Weight rating on Chemours but lowers the price target from $30 to $22.
The lowered price target from $30 to $22 by Barclays suggests a less optimistic outlook for Chemours, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100